Pages

Look Towards A New Future
Showing posts with label Drug. Show all posts
Showing posts with label Drug. Show all posts

Aug 6, 2012

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Leading business intelligence provider GBI Research has released its latest research report, entitled “Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities”. The report provides insights into the substance abuse therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse, as well as insights into the substance abuse therapeutics R&D pipeline. In addition, it analyzes the competitive landscape through the analysis of M&A and licensing deals. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research finds that the substance abuse therapeutics market in the top seven markets was valued at $8.8 billion in 2011, increasing at a CAGR of 4.9% during the review period 2004–2011. The market is projected to witness moderate growth of 5.3% during the 2011–2018 forecast period to reach $12.7 billion. The moderate growth of the market can be attributed to the presence of generics in the market, low compliance with therapy due to the nature of addiction and the lack of innovative products in the pipeline. However, indications such as cocaine addiction, which currently have no approved products, are expected to see entries to the market and high-priced products such as Champix for smoking cessation will not see patent expiry in the forecast period.

Scope
  • Data and analysis on the substance abuse therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the substance abuse therapeutics market from 2004-2011 with forecasts to 2018.
  • Market data on the therapeutic landscape, which covers nicotine addiction, alcohol dependence and opioid and cocaine abuse. This includes market size, annual cost of therapy, treatment flow algorithm.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The competitive landscape of the global substance abuse therapeutics market, which includes companies such as Pfizer, GSK, Forest Laboratories, Alkermes and Reckitt Benckiser.
  • Key M&A activities and licensing agreements that took place from 2007 to 2011 in the global substance abuse therapeutics market.
Reasons to Buy
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and substance abuse therapeutics market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the global substance abuse therapeutics market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Buy your copy of this report @ http://www.reportsnreports.com/reports/184068-substance-abuse-therapeutics-market-to-2018-effective-drug-therapies-in-the-treatment-of-alcohol-and-opioid-dependence-offer-significant-market-opportunities.html

Report Details:
Published: August 2012
Price: Single User License: US$3500        Corporate User License:US10500
Posted by Unknown at 8/06/2012
Labels: , , , ,

Jan 31, 2012

Drug Delivery Systems to 2015

This study analyzes the market for drug delivery systems in the US. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by material (e.g., monoclonal antibodies, synthetic and natural polymers, nanosized particles); type (e.g., oral, parenteral, inhalation, transdermal, implantable); and application. The study also considers market environment factors, details industry structure, evaluates company market share and profiles leading industry players.

US demand to rise 7.2% annually through 2015
US demand for drug delivery products is forecast to expand 7.2 percent annually to $133 billion in 2015. The best growth opportunities will emerge in specialized pharmaceutical formulations and administration devices that advance the nature of therapy for autoimmune conditions, cancer, heart disease, neurological disorders and other debilitating health problems. Included in this group are human monoclonal antibodies, polymer encapsulated nanomedicines and transdermal patches for breakthrough pain management. Infusion products and parenteral delivery devices with improved safety, infection prevention and ease-of-use features will also fare well in the marketplace. Among these devices are retractable syringes, needleless injectors, premixed IV systems and smart infusion pumps. Based on the complex nature of therapy and the high frequency of dosing requirements, central nervous system, respiratory and hormonal indications will command the largest and fastest growth by drug delivery products.

Drug Delivery Systems Report

Published:January 2012
No. of Pages: 200



Request Sample


Chewable and orally disintegrating tablets to see good growth
Demand for oral drug delivery products will increase 4.3 percent annually to over $52 billion in 2015. Controlled-release formulations will command the largest share of sales, but will lose some growth momentum due to patent expirations on several large-selling sustained-release therapies. Chewable and orally disintegrating tablets, nanoparticulate medicines and transmucosal therapies will realize faster growth in demand spurred by new product introductions and the high valueadded nature of indications served.

Monoclonal antibodies to pace parenteral products
Demand for parenteral drug delivery products will reach $54.7 billion in 2015, up eleven percent annually from 2015. Monoclonal antibodies will lead gains as advances in biotechnologies contribute new and improved therapies for autoimmune disorders, cancer and various rate debilitating diseases. Polymer-encapsulated medicines will also see fast rising demand based on contributions to the improved bioavailality and reduced toxicity of advanced parenteral compounds. Safety-engineered prefillable syringes and IV catheters, along with bag/ vial infusion systems, will command the best growth opportunities among parenteral infusion products and delivery devices due largely to infection prevention advantages.

Patches to lead gains among other drug delivery systems
Other drug delivery products will post demand of $26.1 billion in 2015, up 6.6 percent annually from 2010. Prefilled dry powder and metered dose inhalers will retain the largest share of sales, spurred largely upward trends in prevalence of asthma and chronic obstructive pulmonary disease (COPD). Less favorably, growth opportunities for these devices will decelerate as patent expirations open up several widely prescribed inhalation therapies, including sales leader ADVAIR, to generic competition. Led by new next-generation drug-eluting stents with thinner struts and enhanced safety profiles, implantable drug delivery systems will generate rebounding demand in angioplasty procedures, reversing a recent sharp sales drop. Transdermal patches will realize the fastest growth among other drug delivery systems as new therapies for breakthrough pain and various central nervous system disorders replace less effective oral medicines.
Posted by Unknown at 1/31/2012
Labels: , , ,

Oct 6, 2010

Benchmarking The Pharmaceutical Market By Drug Delivery To 2014 Now Available At ReportsandReports

Original Source: Pharmaceutical Market

Buy Now: Market Research

Dallas, TX: ReportsandReports announce it will carry Benchmarking the Pharmaceutical Market by Drug Delivery to 2014 Market Research Report in its Store.

Drug delivery can play an important role at all stages of a drug’s lifecycle and has become an ever present feature in the business model of the leading pharmaceutical companies. Using the PharmaVitae Explorer database, the report provides an in depth sales analysis of the specific routes of administration driving the pharmaceutical market out to 2014

Scope
  • Assess how drug delivery has become an ever present feature in the business model of the leading pharmaceutical companies
  • Provides an insight into the prominent technology types in the expansive drug delivery segment
  • Benchmarks the sales performance of the leading prescription pharmaceutical companies in terms of drug delivery

Highlights

The oral and injectable segments are the dominant routes of administration in the prescription pharmaceutical market, accounting for more than 80% of combined sales in 2008.

Injectables will see the biggest increase in annual sales at $49 billion over 200814. In contrast, oral drugs will collectively decline by $10.9 billion over the same period.

Slow-growth therapy areas are generally entrenched in oral medications. This dynamic is mirrored by the fast-growth therapy areas, where novel injectable drugs will primarily drive growth.

Reasons to Purchase
  • Assess the ways in which drug delivery technology to add value to pharmaceutical products
  • Determine current R&D trends in the drug delivery segment
  • Examine the long-term sales performance of each delivery type across the leading prescription pharmaceutical players

TABLE OF CONTENTS

ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2

Chapter 1 About this report
PharmaVitae Explorer database 3
Chapter structure 4
Data sourcing 4

Chapter 2 Executive summary
Key findings
Drug delivery overview 6
Prescription pharmaceutical market by delivery mechanism, 2002–14 12

Chapter 3 Overview of drug delivery market
Key findings
Introduction to drug delivery 28

Chapter 4 Segmentation of the drug delivery market
Key findings
Segmentation of the drug delivery market 35
Segmentation by mode of delivery 37
Segmentation by technology type 45
Merging technology with commercial opportunity 48

Chapter 5 Sales analysis of the pharmaceutical market by drug delivery
Key findings
A delivery-focused sales analysis of the leading prescription pharmaceutical companies 51
Prescription pharmaceutical market by delivery mechanism 53
Drug delivery analysis of the leading pharmaceutical players by company 67
Drug delivery analysis of the leading pharmaceutical players by company 74

Chapter 6 Appendix
References
Abbreviations 80
Exchange rates 81
About Datamonitor 82
Datamonitor consulting 82
Disclaimer 84


Related Reports:






About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Posted by Unknown at 10/06/2010
Labels: , , , , , , , , ,